<DOC>
	<DOCNO>NCT02971618</DOCNO>
	<brief_summary>The study retrospectively collect clinical variable socio-demographic data medical record patient T2DM initiate treatment dapagliflozin previous failure/inefficiency treatment option ( define non-achievement target Hb1Ac ) accord officially approve indication per instruction use medicinal product . It expect best available data regard clinical variable patient socio-demographic profile collected patient medical record 40 major Russian outpatient clinics/centers specialize treatment management T2DM patient . There 2 time point : - Baseline data : baseline data define data available within 3 month prior first dose dapagliflozin . In case presence multiple data value within baseline period recent pre-dose value select - Follow-up data : post-baseline data consider follow-up primary analysis focus data available 6 plus/minus 3 month initiation dapagliflozin . In case discontinuation dapagliflozin , data collect routine visit within 3-month time frame last dose .</brief_summary>
	<brief_title>Study With Dapagliflozin</brief_title>
	<detailed_description>Objectives Hypotheses : Primary objective : To describe HbA1c ( glycosylated haemoglobin ) change baseline follow-up Secondary objective : Clinical data : - To estimate percentage ( % ) patient reduction HbA1c 0.5 % baseline follow-up - To estimate percentage ( % ) patient reach therapeutic glycemic response ( HbA1c &lt; 7.0 % ) baseline follow-up - To describe change fast blood glucose baseline follow-up - To estimate change body weight baseline follow-up - To estimate percentage ( % ) patient body weight reduction least 5 % baseline follow-up - To estimate percentage ( % ) patient reduction HbA1c 0.5 % body weight reduction least 5 % baseline follow-up - To describe change systolic diastolic blood pressure baseline follow-up ( systolic diastolic , mmHg ) Methods : Study design : The study retrospectively collect clinical variable socio-demographic data medical record patient T2DM initiate treatment dapagliflozin previous failure/inefficiency treatment option ( define non-achievement target Hb1Ac ) accord officially approve indication per instruction use medicinal product . It expect best available data regard clinical variable patient socio-demographic profile collected patient medical record 40 major Russian outpatient clinics/centers specialize treatment management T2DM patient . There 2 time point : - Baseline data : baseline data define data available within 3 month prior first dose dapagliflozin . In case presence multiple data value within baseline period recent pre-dose value select - Follow-up data : post-baseline data consider follow-up primary analysis focus data available 6 plus/minus 3 month initiation dapagliflozin . In case discontinuation dapagliflozin , data collect routine visit within 3-month time frame last dose . Data Source ( ) : Participating investigator physicians-endocrinologists work approximately 12 outpatient clinic specialized management patient T2DM Moscow . There current legislation EMR Russia , , paper medical record utilize , data collection use electronic CRFs do . Study Population : T2DM patient previously uncontrolled standard therapy ( mono- , double therapy OADs : metformin , SU DPP-4 inhibitor insulin ) initiate treatment dapagliflozin monotherapy , combination OADs add-on insulin available data Hb1c within 3 month prior first dose dapagliflozin . All consecutive patient clinic inclusion period meet inclusion exclusion criterion include . Exposure ( ) : Only patient initiate treatment dapagliflozin monotherapy , combination OADs add-on insulin include study . Outcome ( ) : Population parameter - Date birth - Gender - Level education - Level income - Ethnicity/race - Living condition - Working condition All document macro- microvascular T2DM complication concomitant medication ( antidiabetic drug , statin , ACE inhibitor , sartans , beta-blockers , calcium channel antagonist ) collect whole course dapagliflozin administration . Clinical parameter - Hb1Ac - Fasting glucose - Body weight - Blood pressure ( systolic diastolic ) Sample Size Estimations : Approximate sample size 850 patient . Statistical Analysis : Epidemiological method mainly use represent study data . A descriptive analysis approach use analyse study objective . Descriptive statistic use analyse study population , baseline data clinical outcome . The descriptive statistic include mean , standard deviation , median , minimum maximum , range , number valid case continuous variable , number , percentage , distribution categorical variable . The percentage give relevant two-sided 95 % confidence interval . Only available data analyze ; miss value imputation apply . Only patient available data HbA1c within 3 month prior first dose dapagliflozin 6±3 month initiation dapagliflozin include main analysis . All baseline , effectiveness parameter tabulate , assess subgroup available.. In order evaluate association achievement HbA1C goal patient characteristic , multivariate logistic regression model develop . A binary categorical attribute-HbA1C within/outside &lt; 7 % 6±3 month initiation dapagliflozin -serves dependable variable model .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients Type 2 Diabetes Mellitus Male female , age 1865 year ( inclusive ) Patients T2DM give first prescription dapagliflozin Dec 2014 till 1 October 2016 Type 1 diabetes Contraindications SGLT 2 inhibitor ( high individual sensitivity SGLT 2 inhibitor , T1DM , diabetic ketoacidosis , moderate severe renal failure ( eGFR &lt; 60 ml/min/1.73 m3 ) , endstage renal disease , lactose intolerance , intolerance glucose galactose , pregnancy breast feeding , age young 18 year old , use loop diuretic , decrease circulate blood volume due acute disease , age 77 year old old Prior use SGLT 2 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>dapagliflozin ,</keyword>
	<keyword>Russia ,</keyword>
	<keyword>retrospective study ,</keyword>
	<keyword>diabetes mellitus type 2</keyword>
</DOC>